Takeda Pharmaceutical Co (FRA:TKD) Cyclically Adjusted Book per Share: €21.24 (As of Mar. 2026)


FRA:TKD Takeda Pharmaceutical Co Ltd FRA:TKD
65 GF Score
Price €29.21
GF Value €24.32
Valuation Modestly Overvalued
! 10 Warning Signs
View Full Analysis

What is Takeda Pharmaceutical Co Cyclically Adjusted Book per Share?

Takeda Pharmaceutical Co FRA:TKD -0.14% 65 Cyclically Adjusted Book per Share is €21.24 as of Mar. 2026. GuruFocus rates FRA:TKD with a GF Score™ of 65/100 and a GF Value™ of €24.32 (Modestly Overvalued). The stock has 10 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Takeda Pharmaceutical Co's adjusted book value per share for the three months ended in Mar. 2026 was €25.635. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €21.24 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Takeda Pharmaceutical Co's average Cyclically Adjusted Book Growth Rate was 5.80% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 6.50% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 6.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Takeda Pharmaceutical Co was 7.10% per year. The lowest was 1.30% per year. And the median was 4.00% per year.

As of today (2026-07-08), Takeda Pharmaceutical Co's current stock price is €29.21. Takeda Pharmaceutical Co's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was €21.24. Takeda Pharmaceutical Co's Cyclically Adjusted PB Ratio of today is 1.38.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Takeda Pharmaceutical Co was 2.42. The lowest was 1.03. And the median was 1.34.


Takeda Pharmaceutical Co  (FRA:TKD) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Takeda Pharmaceutical Co's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=29.21/21.24
=1.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Takeda Pharmaceutical Co was 2.42. The lowest was 1.03. And the median was 1.34.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Takeda Pharmaceutical Co Cyclically Adjusted Book per Share Related Terms


Takeda Pharmaceutical Co Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Takeda Pharmaceutical Co's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Takeda Pharmaceutical Co Cyclically Adjusted Book per Share Chart

Takeda Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.62 21.89 20.76 22.16 21.24

Takeda Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.16 21.62 21.19 20.39 21.24

FRA:TKD vs ZTS, UTHR: Cyclically Adjusted Book per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Takeda Pharmaceutical Co's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Takeda Pharmaceutical Co Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Takeda Pharmaceutical Co's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Takeda Pharmaceutical Co's Cyclically Adjusted PB Ratio falls into.


FRA:TKD
65GF Score
Takeda Pharmaceutical Co Ltd FRA:TKD
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Takeda Pharmaceutical Co Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Takeda Pharmaceutical Co's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=25.635/112.7000*112.7000
=25.635

Current CPI (Mar. 2026) = 112.7000.

Takeda Pharmaceutical Co Quarterly Data

Book Value per Share CPI Adj_Book
201606 19.499 98.100 22.401
201609 20.321 98.000 23.369
201612 20.665 98.400 23.668
201703 20.088 98.100 23.078
201706 20.696 98.500 23.680
201709 20.222 98.800 23.067
201712 20.242 99.400 22.950
201803 19.551 99.200 22.212
201806 20.341 99.200 23.109
201809 21.217 99.900 23.935
201812 20.442 99.700 23.107
201903 26.539 99.700 29.999
201906 25.653 99.800 28.969
201909 26.373 100.100 29.693
201912 25.801 100.500 28.933
202003 25.487 100.300 28.638
202006 24.750 99.900 27.921
202009 23.980 99.900 27.053
202012 23.481 99.300 26.650
202103 25.571 99.900 28.847
202106 25.172 99.500 28.511
202109 26.118 100.100 29.406
202112 26.612 100.100 29.962
202203 27.903 101.100 31.105
202206 28.852 101.800 31.941
202209 30.440 103.100 33.274
202212 27.798 104.100 30.094
202303 28.562 104.400 30.833
202306 29.070 105.200 31.142
202309 28.562 106.200 30.310
202312 27.368 106.800 28.880
202403 28.466 107.200 29.926
202406 29.249 108.200 30.465
202409 27.517 108.900 28.477
202412 29.056 110.700 29.581
202503 27.348 111.100 27.742
202506 26.374 111.700 26.610
202509 26.012 112.000 26.175
202512 26.502 113.000 26.432
202603 25.635 112.700 25.635

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €21.24 mean?
Takeda Pharmaceutical Co (FRA:TKD) has a Cyclically Adjusted Book per Share of €21.24 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Takeda Pharmaceutical Co and its competitors.
Is Takeda Pharmaceutical Co's Cyclically Adjusted Book per Share too high?
Takeda Pharmaceutical Co's current Cyclically Adjusted Book per Share is €21.24. Overall, Takeda Pharmaceutical Co has a GF Score™ of 65/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Takeda Pharmaceutical Co's Cyclically Adjusted Book per Share compare to ZTS and UTHR?
Takeda Pharmaceutical Co's Cyclically Adjusted Book per Share of €21.24 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Book per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Takeda Pharmaceutical Co and its competitors. Takeda Pharmaceutical Co's current Cyclically Adjusted Book per Share is €21.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Takeda Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Takeda Pharmaceutical Co (FRA:TKD) is currently considered Modestly Overvalued. The stock's GF Value™ is €24.32, compared to a current price of €29.21 — trading 20.1% above its estimated fair value. The current Cyclically Adjusted Book per Share is €21.24. Takeda Pharmaceutical Co's overall GF Score™ is 65/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Takeda Pharmaceutical Co (FRA:TKD), the current Cyclically Adjusted Book per Share is €21.24 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Takeda Pharmaceutical Co (FRA:TKD) Overvalued in 2026?

Based on GuruFocus' analysis, Takeda Pharmaceutical Co stock appears to be overvalued. The current stock price of €29.21 is trading 20.1% above its estimated GF Value™ of €24.32. GuruFocus considers Takeda Pharmaceutical Co to be Modestly Overvalued.

Key valuation signals for FRA:TKD:

  • Cyclically Adjusted Book per Share: €21.24
  • GF Value™: €24.32 vs. price of €29.21 (20.1% above fair value)
  • GF Score™: 65/100 with 10 warning signs

No single metric tells the full story. See the FRA:TKD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Takeda Pharmaceutical Co Business Description

Address 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, JPN, 103-8668
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.
65GF Score

Get the complete analysis for FRA:TKD

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€29.21
Price
€24.32
GF Value